Friedman M, Cassidy M, Levine M, Phillips T, Spivack S, Resser K J
Cancer. 1979 Sep;44(3):906-13. doi: 10.1002/1097-0142(197909)44:3<906::aid-cncr2820440318>3.0.co;2-9.
Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2.5-10 mg/m2/day) as part of a Phase I-II study. Of the 21 patients who completed therapy, 19 had colorectal carcinoma and 2 had metastatic adenocarcinoma of unknown origin. Objective response was judged by measurement of liver size, evaluation of liver function tests, and by liver scan or CAT scan of the liver. Ten of the 21 evaluable patients responded, yielding an overall response rate of 47.6%. The response rate in patients with colorectal carcinoma was 55% (10/19). At this time, median duration of response is 14+ weeks and median survival from onset of therapy is 15+ weeks. Hematologic and gastrointestinal toxicity were tolerable. No hepatic toxicity was documented. This combined modality therapy was found to be a safe effective method for the palliation of liver metastasis.
作为一项I-II期研究的一部分，22例肝转移腺癌患者接受了快速分割全肝照射（每次300拉德，共1350 - 2100拉德），同时肝内给予5-氟尿嘧啶（10 - 15毫克/千克/天）和阿霉素（2.5 - 10毫克/平方米/天）。在完成治疗的21例患者中，19例为结直肠癌，2例为来源不明的转移性腺癌。通过测量肝脏大小、评估肝功能检查以及肝脏扫描或肝脏计算机断层扫描来判断客观缓解情况。21例可评估患者中有10例有反应，总缓解率为47.6%。结直肠癌患者的缓解率为55%（10/19）。此时，缓解的中位持续时间为14 +周，从治疗开始的中位生存期为15 +周。血液学和胃肠道毒性是可耐受的。未记录到肝毒性。这种综合治疗方法被发现是缓解肝转移的一种安全有效的方法。
